The Filing Desk

PMGC Holdings vs Silence Therapeutics

PMGC Holdings ELAB · Silence Therapeutics SLN · Biotechnology

PMGC Holdings reported revenue of $1 million in fiscal 2025, about the same as Silence Therapeutics' $1 million in fiscal 2025. Free cash flow was −$6 million at PMGC Holdings and −$62 million at Silence Therapeutics.

Side by side

PMGC HoldingsSilence Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1M$1M
Revenue growth—−98.7%
Revenue growth a year, last 5 years——
Gross margin31.4%61.5%
Operating margin—−16,292.8%
Net margin−1,313.0%−15,851.9%
Free cash flow−$6M−$62M
Free cash flow margin−1,080.5%−11,149.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count2,049.1%2.1%
Last close$1.27$19.81
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
PMGC HoldingsSilence Therapeutics
Operating margin
Percent of revenue
PMGC HoldingsSilence Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
PMGC HoldingsSilence Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the PMGC Holdings and Silence Therapeutics pages.